(Reuters) - Eli Lilly and Co said on Monday it started a late-stage trial testing whether one of its experimental COVID-19 antibody treatments can prevent the spread of infections in residents and ...

Drugmaker Eli Lilly said Thursday its antibody drug can prevent COVID-19 illness in residents and staff of nursing homes and other long-term care locations. It's the first major study to show such a ...

With a coronavirus vaccine still months off, companies are rushing to test what may be the next best thing: drugs that deliver antibodies to fight the virus right away, without having to train the ...

The Food and Drug Administration (FDA) announced Friday that it has issued emergency use authorization (EUA) for Eli Lilly's new monoclonal antibody treatment. Clinical trials have shown the treatment ...

Feb 9 (Reuters) - Eli Lilly's (LLY.N), opens new tab combination antibody therapy to fight COVID-19 has been granted emergency use authorization by the U.S. Food and Drug Administration, Lilly said on ...

But Eli Lilly's Zepbound is best in class. Zepbound caused greater average weight loss than Wegovy in a head-to-head study.